Santen Pharmaceutical Co., Ltd. (4536) – Financial and Strategic SWOT Analysis Review

Santen Pharmaceutical Co., Ltd. (4536) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $300

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
58
Pharmaceuticals and Healthcare
Japan

Santen Pharmaceutical Co., Ltd. (4536) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Santen Pharmaceutical Co., Ltd. (Santen) is a pharmaceutical company. It focuses on the development and manufacture of pharmaceutical products and medical devices. Santen specializes in ophthalmological products. Its product portfolio includes prescription ophthalmic products, anti-rheumatics, OTC drugs, anti-allergy ophthalmic products, prescription anti-rheumatic drugs and medical devices such as intraocular lenses, among others. The company markets its products under brand names such as Livostin, Alesion, Metadate, Cravit, Diquas and Hyalein, among others. It has manufacturing plants and laboratories in France, Japan, China, Finland and the US.

Santen Pharmaceutical Co., Ltd. Key Recent Developments

Mar 10, 2015 Santen Pharmaceutical Announces Appointment Of Corporate Officers
Feb 25, 2015 Santen Chooses NTT Communications’ Hybrid-cloud ICT Infrastructure for Global Growth
Feb 02, 2015 Santen Launches Sante Lutax 20 +Vitamin & Mineral, a Nutritional Supplement Containing Lutein
Nov 05, 2014 Santen Pharmaceutical Announces Second Quarter Financial Results For The Fiscal Year Ending March 31, 2015

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Santen Pharmaceutical Co., Ltd. – Key Facts 6
Santen Pharmaceutical Co., Ltd. – Key Employees 7
Santen Pharmaceutical Co., Ltd. – Major Products and Services 8
Santen Pharmaceutical Co., Ltd. – Pharmaceutical Pipeline Products Data 10
Santen Pharmaceutical Co., Ltd., Pipeline Products by Therapy Area 10
Santen Pharmaceutical Co., Ltd., Pipeline Products by Development Phase 11
Santen Pharmaceutical Co., Ltd. – History 13
Santen Pharmaceutical Co., Ltd. – Company Statement 19
Santen Pharmaceutical Co., Ltd. – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Section 2 – Company Analysis 26
Santen Pharmaceutical Co., Ltd. – Business Description 26
Santen Pharmaceutical Co., Ltd. – Corporate Strategy 27
Santen Pharmaceutical Co., Ltd. – SWOT Analysis 28
SWOT Analysis – Overview 28
Santen Pharmaceutical Co., Ltd. – Strengths 28
Strength – Focus on Ophthalmological Indications 28
Strength – In-house Research Expertise 28
Strength – Strong Presence across Asia 28
Santen Pharmaceutical Co., Ltd. – Weaknesses 29
Weakness – Product Discontinuations 29
Weakness – Dependence on Few Customers 29
Santen Pharmaceutical Co., Ltd. – Opportunities 30
Opportunity – Robust Pipeline 30
Opportunity – Product Acquisitions 30
Opportunity – Market Potential: Age-related Macular Degeneration (AMD) 30
Santen Pharmaceutical Co., Ltd. – Threats 31
Threat – Dependence on In-licensed Products 31
Threat – Launch of Generic Products 31
Threat – Dependence on Third Parties 31
Santen Pharmaceutical Co., Ltd. – Key Competitors 32
Section 3 – Company Financial Ratios 33
Financial Ratios – Capital Market Ratios 33
Financial Ratios – Annual Ratios 34
Performance Chart 36
Financial Performance 36
Financial Ratios – Interim Ratios 37
Financial Ratios – Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 39
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 40
Santen Pharmaceutical Co., Ltd., Recent Deals Summary 41
Section 5 – Company’s Recent Developments 42
Mar 10, 2015: Santen Pharmaceutical Announces Appointment Of Corporate Officers 42
Feb 25, 2015: Santen Chooses NTT Communications’ Hybrid-cloud ICT Infrastructure for Global Growth 43
Feb 02, 2015: Santen Launches Sante Lutax 20 +Vitamin & Mineral, a Nutritional Supplement Containing Lutein 45
Nov 05, 2014: Santen Pharmaceutical Announces Second Quarter Financial Results For The Fiscal Year Ending March 31, 2015 46
Nov 05, 2014: Santen Pharmaceutical Announces Consolidated Performance For Nine Months Ended 31 December 2014 47
Oct 31, 2014: Santen Receives Financing from the Development Bank of Japan based on DBJ Environmental Rating 48
Sep 25, 2014: Increase of Capital for a Consolidated Subsidiary in Europe 49
Sep 09, 2014: Santen Launches Soft Santear Hitomi Stretch, an Eye Drop for Use with Soft Contact Lenses to Reduce Eyestrain by Relaxing Ciliary Muscle Stiffness Which Can Be a Cause of Eyestrain 50
Aug 05, 2014: Santen Pharmaceutical Announces First Quarter Financial Results For The Fiscal Year Ending March 31, 2015 51
Aug 05, 2014: Santen Pharmaceutical Announces Medium-Term Management Plan FY2014-2017 52
Section 6 – Appendix 54
Methodology 54
Ratio Definitions 54
About GlobalData 58
Contact Us 58
Disclaimer 58



List of Tables
Santen Pharmaceutical Co., Ltd., Key Facts 6
Santen Pharmaceutical Co., Ltd., Key Employees 7
Santen Pharmaceutical Co., Ltd., Major Products and Services 8
Santen Pharmaceutical Co., Ltd., Number of Pipeline Products by Therapy Area 10
Santen Pharmaceutical Co., Ltd., Number of Pipeline Products by Development Stage 11
Santen Pharmaceutical Co., Ltd., Pipeline Products By Therapy Area and Development Phase 12
Santen Pharmaceutical Co., Ltd., History 13
Santen Pharmaceutical Co., Ltd., Other Locations 23
Santen Pharmaceutical Co., Ltd., Subsidiaries 24
Santen Pharmaceutical Co., Ltd., Key Competitors 32
Santen Pharmaceutical Co., Ltd., Ratios based on current share price 33
Santen Pharmaceutical Co., Ltd., Annual Ratios 34
Santen Pharmaceutical Co., Ltd., Interim Ratios 37
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 39
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 40
Santen Pharmaceutical Co., Ltd., Recent Deals Summary 41
Currency Codes 54
Capital Market Ratios 54
Equity Ratios 55
Profitability Ratios 55
Cost Ratios 56
Liquidity Ratios 56
Leverage Ratios 57
Efficiency Ratios 57



List of Figures
Santen Pharmaceutical Co., Ltd., Pipeline Products by Therapy Area 10
Santen Pharmaceutical Co., Ltd., Pipeline Products by Development Phase 11
Santen Pharmaceutical Co., Ltd., Performance Chart (2010 – 2014) 36
Santen Pharmaceutical Co., Ltd., Ratio Charts 38
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 39
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 40

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $300

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.